Norimitsu Kasahara1, Noriaki Sunaga2, Yusuke Tsukagoshi2, Yosuke Miura2, Reiko Sakurai3, Shinsuke Kitahara2, Takehiko Yokobori4, Kyoichi Kaira5, Akira Mogi6, Toshitaka Maeno2, Takayuki Asao7, Takeshi Hisada8. 1. Innovative Medical Research Center, Gunma University Hospital, Maebashi, Japan m14702016@gunma-u.ac.jp. 2. Department of Respiratory Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan. 3. Oncology Center, Gunma University Hospital, Maebashi, Japan. 4. Department of Innovative Cancer Center Immunotherapy, Gunma University, Maebashi, Japan. 5. Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Japan. 6. Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Japan. 7. Innovative Medical Research Center, Gunma University Hospital, Maebashi, Japan. 8. Gunma University, Graduate School of Health Sciences, Maebashi, Japan.
Abstract
BACKGROUND/AIM: No definitive biomarker exists for predicting treatment efficacy or response to therapy with antibody to programmed cell death-1 (PD1) for patients with advanced non-small cell lung cancer (NSCLC). Hence, we investigated whether the Glasgow prognostic score (GPS) predicted anti-PD1 treatment response for advanced NSCLC. PATIENTS AND METHODS: This study retrospectively identified 47 patients with NSCLC treated with anti-PD1 and assessed the prognostic value of the GPS. The GPS was calculated using C-reactive protein and albumin concentrations 1 month after starting anti-PD1 treatment. Kaplan-Meier method and Cox proportional hazard models were used to examine differences in progression-free (PFS) and overall (OS) survival, and clinical response. RESULTS: The post-treatment GPS independently predicted anti-PD1 treatment efficacy, as a good post-treatment GPS (GPS 0-1) was significantly associated with improved PFS. Intra-treatment GPS change was associated with clinical response. CONCLUSION: The post-treatment GPS independently predicted efficacy of anti-PD1 treatment for NSCLC. Copyright
BACKGROUND/AIM: No definitive biomarker exists for predicting treatment efficacy or response to therapy with antibody to programmed cell death-1 (PD1) for patients with advanced non-small cell lung cancer (NSCLC). Hence, we investigated whether the Glasgow prognostic score (GPS) predicted anti-PD1 treatment response for advanced NSCLC. PATIENTS AND METHODS: This study retrospectively identified 47 patients with NSCLC treated with anti-PD1 and assessed the prognostic value of the GPS. The GPS was calculated using C-reactive protein and albumin concentrations 1 month after starting anti-PD1 treatment. Kaplan-Meier method and Cox proportional hazard models were used to examine differences in progression-free (PFS) and overall (OS) survival, and clinical response. RESULTS: The post-treatment GPS independently predicted anti-PD1 treatment efficacy, as a good post-treatment GPS (GPS 0-1) was significantly associated with improved PFS. Intra-treatment GPS change was associated with clinical response. CONCLUSION: The post-treatment GPS independently predicted efficacy of anti-PD1 treatment for NSCLC. Copyright
Authors: Yizhen Guo; Lai Wei; Sandip H Patel; Gabrielle Lopez; Madison Grogan; Mingjia Li; Tyler Haddad; Andrew Johns; Latha P Ganesan; Yiping Yang; Daniel J Spakowicz; Peter G Shields; Kai He; Erin M Bertino; Gregory A Otterson; David P Carbone; Carolyn Presley; Samuel K Kulp; Thomas A Mace; Christopher C Coss; Mitch A Phelps; Dwight H Owen Journal: Clin Lung Cancer Date: 2022-01-08 Impact factor: 4.840
Authors: Giuseppe Luigi Banna; Alex Friedlaender; Marco Tagliamento; Veronica Mollica; Alessio Cortellini; Sara Elena Rebuzzi; Arsela Prelaj; Abdul Rafeh Naqash; Edouard Auclin; Lucia Garetto; Laura Mezquita; Alfredo Addeo Journal: Curr Oncol Rep Date: 2022-10-18 Impact factor: 5.945
Authors: Hye Seon Kang; Ah Young Shin; Chang Dong Yeo; Sung Kyoung Kim; Chan Kwon Park; Ju Sang Kim; Seung Joon Kim; Sang Haak Lee; Jin Woo Kim Journal: In Vivo Date: 2021 Nov-Dec Impact factor: 2.155
Authors: Jacqueline T Brown; Yuan Liu; Julie M Shabto; Dylan Martini; Deepak Ravindranathan; Emilie Elise Hitron; Greta Anne Russler; Sarah Caulfield; Lauren Yantorni; Shreyas Subhash Joshi; Haydn Kissick; Kenneth Ogan; Bassel Nazha; Bradley C Carthon; Omer Kucuk; Wayne B Harris; Viraj A Master; Mehmet Asim Bilen Journal: J Immunother Cancer Date: 2021-07 Impact factor: 13.751